JQ-1 or I-BET treatment leads to the transcriptional suppression of MYC target genes, resulting in antitumor effects in MYC-driven models of AML (Dawson et al., 2011; Zuber et al., 2011), Burkitt’s lymphoma (Mertz et al., 2011) and multiple myeloma (Delmore et al., 2011). Here, MYC is linked to AL amyloidosis.